纳武利尤单抗联合小分子抗血管生成药物的不良反应药物警戒分析
本研究基于FDA不良事件报告系统数据库2012年第一季度至2023年第三季度的数据,采用报告比值比(ROR)和Ro/e比值评估纳武利尤单抗联合小分子抗血管生成TKIs的不良反应风险信号。结果显示联合治疗显著增加敏感皮肤、转移性肾细胞癌和肾细胞癌的风险,并比较了不同药物组合及肿瘤类型间的不良反应差异及致死性不良反应患者特征。
要点
- 联合治疗显著增加敏感皮肤风险(ROR 231.43,95%CI 55.01-973.72,P<.05)。
- 联合治疗显著增加转移性肾细胞癌风险(ROR 220.71,95%CI 28.99-1695.41,P<.05)。
- 联合治疗显著增加肾细胞癌风险(ROR 188.22,95%CI 44.24-800.85,P<.05)。
核心结论
- 纳武利尤单抗联合小分子抗血管生成TKIs可显著增加敏感皮肤、转移性肾细胞癌和肾细胞癌的不良反应风险信号。
- 研究结果为理解联合治疗常见不良反应及制定筛查方案提供了参考。
研究设计与样本
- 基于FDA不良事件报告系统数据库的回顾性药物警戒研究,数据覆盖2012年第一季度至2023年第三季度。
- 采用报告比值比(ROR)评估不良反应风险信号,并计算Ro/e比值比较不同肿瘤类型间致死性不良反应风险差异。
主要发现
- 联合治疗显著增加敏感皮肤风险(ROR 231.43,95%CI 55.01-973.72,P<.05)。
- 联合治疗显著增加转移性肾细胞癌风险(ROR 220.71,95%CI 28.99-1695.41,P<.05)。
- 联合治疗显著增加肾细胞癌风险(ROR 188.22,95%CI 44.24-800.85,P<.05)。
- 研究比较了不同小分子药物组合及不同肿瘤类型患者的不良反应差异,并分析了易发生致死性不良反应的患者特征。
临床怎么用
- 临床应关注纳武利尤单抗联合小分子抗血管生成TKIs治疗时敏感皮肤及肾细胞癌相关不良反应的监测与筛查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Immune checkpoint inhibitors, such as nivolumab, combined with small molecule antiangiogenic receptor tyrosine kinase inhibitors (TKIs), present a promising strategy for future immunotherapy. However, combination therapy can lead to specific adverse drug reactions (ADRs) in various clinical settings. Current research on the ADRs associated with combination therapy is limited. Our study aims to assess the safety of combination therapy. METHODS: We extracted ADR reports on combination therapy from the Food and Drug Administration (FDA) Adverse Event Reporting System database, covering the period from the first quarter of 2012 to the third quarter of 2023, and conducted a large-scale retrospective study. We evaluated ADR risk signals using the reporting odds ratio (ROR) and calculated the Ro/e ratio to compare the differences in the risk of fatal ADRs among various tumour types. RESULTS: We comprehensively reported the occurrence of ADRs in pan-cancer patients undergoing combination therapy. The combination therapy significantly increased the risk of sensitive skin (ROR: 231.43, 95% CI: 55.01-973.72, P < .05), metastatic renal cell carcinoma (ROR: 220.71, 95% CI: 28.99-1695.41, P < .05) and renal cell carcinoma (ROR: 188.22, 95% CI: 44.24-800.85, P < .05). We also compared the differences in ADRs resulting from different small molecule drug combinations, as well as the differences in ADRs among patients with different types of tumours under combination therapy. Furthermore, we analysed the characteristics of patients prone to experiencing fatal ADRs. CONCLUSION: These results can help enhance understanding of the ADRs commonly associated with combination therapy and assist oncologists in formulating screening protocols.
引用
- Li H, Ruan Z, Jia Y, et al. Adverse reactions associated with nivolumab and small molecule antiangiogenic drugs: A pharmacovigilance analysis. Br J Clin Pharmacol. 2024. PMID: 39286997. doi:10.1111/bcp.16242
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。